Triton Pacific Healthcare Partners, a notable healthcare-focused private equity group, has successfully concluded the sale of BioMatrix Specialty Infusion Pharmacy to Frazier Healthcare Partners. While the terms of the transaction remain undisclosed, Triton Pacific achieved a significant return of 3.0x on its investment.

Since acquiring BioMatrix in 2016, Triton Pacific has played a pivotal role in the company’s expansion and diversification. Headquartered in Plantation, Florida, BioMatrix is recognized as one of the largest independent providers of specialty infusion services in the United States, serving patients nationwide across all 50 states. The company has markedly enhanced its service offerings through five strategic acquisitions under Triton Pacific’s ownership. These acquisitions have broadened BioMatrix’s therapeutic scope, bolstered management capabilities, secured new payer contracts, expanded its drug portfolio, and enhanced its infusion operations.

In early 2023, BioMatrix strategically divested its lower-margin traditional specialty business to focus more intently on the specialty infusion sector, a domain experiencing rapid growth and significant market demand. This shift has catalyzed exceptional organic growth, with BioMatrix’s revenue expanding approximately five times faster than the broader infusion industry average.

Throughout its evolution, BioMatrix has maintained a steadfast commitment to high-touch, patient-centric care. The company’s therapeutic centers of excellence are specifically designed to provide superior management of complex patient therapies in areas such as immunology, neurology, oncology, and rare diseases, among others. This focus on specialized patient care has been a constant, even as the company pursued expansive growth and operational enhancements.

Kathee Kramm, who joined BioMatrix as Chief Executive Officer in 2023, highlighted the fruitful collaboration with Triton Pacific: “It has been a pleasure to work with Triton Pacific since joining BioMatrix. The partnership between Triton and our extremely talented, hardworking staff has been instrumental in our rapid growth over the last 12 months. The culture at BioMatrix truly revolves around the patient, putting their needs above all else. I am extremely proud of where we are today and very excited to watch the organization continue to reach new highs and unprecedented levels of growth.”

With an elite management team at the helm, led by CEO Kathee Kramm, BioMatrix is well-positioned for continued success in the specialty infusion market. The sale to Frazier Healthcare Partners marks a new chapter that promises further growth and innovation in patient care services.

Houlihan Lokey, under the leadership of Mike Pisani, acted as the financial advisor for BioMatrix during this transaction, while DLA Piper, led by Josh Kaye, provided legal counsel.

As BioMatrix transitions under the new ownership of Frazier Healthcare Partners, the industry watches eagerly to see how this new synergy will propel the company towards greater achievements in the healthcare sector.

  BioMatrix Specialty Infusion Pharmacy, Frazier Healthcare Partners, Healthcare Investment, specialty infusion services, Triton Pacific Healthcare Partners